Buteyko Patents and Trademarks

Buteyko Patents and Trademarks by Vladimir K. Buteyko

Citation
, XML
Authors

Abstract

Buteyko Patents and Trademarks: How to stand up to threats from “rights holders” an Open Letter from Vladimir K. Buteyko. 
SUMMARY: The Buteyko method is a set of principles and rules for breathing normalisation that can be adapted to the needs of individual patients. As such it is difficult to protect by patent. Moreover, descriptions of the methods have been widely available in accessible books etc prior to the date of any patent. 
The Buteyko trademark, at least in some countries, covers only medical treatment, whereas training (which is what practitioners do) is not covered. Any practitioner with a company name or internet domain name incorporating the Buteyko name, prior to 2004 is likely to have priority rights. Moreover, the trademark applies to the word “BUTEYKO” for a designation of service. “If the practitioner refers instead to author for example: “the method by Buteyko” or ” the Buteyko’s method “, etc, the trademark’s threats should not apply.” (See below for more detail)

Buteyko Patents and Trademarks

How to stand up to threats from “rights holders” by Vladimir K. Buteyko

Vladimir K. Buteyko
Vladimir K. Buteyko, Director of Buteyko Co Ltd (Voronezh) since 1991. He is at the same time senior lecturer at Voronezh State University, where he has been teaching since 1985. He holds the degree of the Candidate of Physical and Mathematical Sciences and is the author of more than 70 scientific publications, including 9 inventions.
Vladimir K. Buteyko is the elder son of K.P. Buteyko.
Address: Buteyko Co Ltd, 7, pr. Revolutsii,
Voronezh 394000, Russian Federation.
Email: mail@buteyko.vrn.ru 
Website: http://www.buteyko.ru/eng/voronezh/index.shtml
Several practitioners have informed me that they have received demands for payment for teaching the Buteyko Method. These demands have been accompanied by threats of legal prosecution for the supposed infringement of patent and trademarks. The practitioners have requested clarification OF WHAT GROUNDS THESE THREATS ARE BASED ON and how they can protect themselves against blackmail.
The clarifications that I will give may be used in their entirety by practitioners teaching the authentic (correct) Buteyko Method – i.e. the breath correction method, and not the pseudoscientific “CO2 accumulation” and infamous “breathing gymnastics”, “breathing training devices” and so on. The latter may also use those recommendations that do not concern the substance of the methodology.

No threats have been made in respect of 
copyright, so we will limit our discussion to patents and trademarks. 

Patents

A specific feature of the Buteyko Method is that the essence  of its application cannot be restricted by patents. This relates to the fact that Dr Buteyko understood the word “method” not to mean a “technique” as such but a methodology, i.e. a set of principles and rules that he discovered. Once these principles and rules are understood, they can be used to generate various sets of methods, techniques etc that are unique to each specific patient and to each specific situation.

At the same time, modern legislation is constructed in such a way that methodologies, sets of principles, theories and other such products of intellectual activity are not protected by law. Nor is it possible to patent the majority of methods and techniques used by practitioners as descriptions have long been available, i.e. published in accessible media such as books [1-5 and others].

Trademarks

The law provides for trademarks not to encourage market monopolies, but on the contrary to allow goods (and services) to be individualised. In other words, the aim of a trademark is to prevent confusion – i.e. to allow consumers to differentiate between the symbol of the services of one provider from the symbol of the services of another.

We should also bear in mind that laws were not created with blatantly dishonest people in mind.

It follows from the above that practitioners do not need to be afraid of threats if they take some elementary precautions.

What practitioners need to do

The root cause of fear is ignorance and uncertainty. The first step should be therefore be to study the documents used as threats against practitioners and the points of law relating to same. When writing about legislation, I will obviously have Russian law in mind. However, it is also evident that if laws in other countries do differ, it is only in tiny details and particulars.

Of course, to a person who has never been involved in legal proceedings, a claim submitted by another party to a court comes like a bolt from the blue. The mere accusation of breaking the law can be enough to disturb an honest person’s equilibrium. However, if his conscience is clear, innocence can be proven with very little brainwork.

The fact is that the legal system is very amiably biased towards the defendant and not the claimant. In particular, in order for a court to initiate proceedings, the claimant must:
1. Provide EVIDENCE of his rights;
2. Provide CONCRETE EVIDENCE that his rights were infringed by the defendant.

Moreover, ANY DOUBTS are always interpreted IN FAVOUR OF THE DEFENDANT and not the claimant.
 
Now let’s take a close look at the documents themselves, beginning with patents. According to my information, the threats from the “intimidators” make reference to patent RF No. 245171 (Appendix 1) for “THE METHOD OF K.P. BUTEYKO FOR TREATING HYPOCARBIC DISEASES AND STATES”, priority date 29.04.2004. If the patent is registered abroad, the practitioner needs to examine the version in force in his country.

Our first glance at the date and name of this patent completely reveals the dishonesty of its authors. How could they write “The Method of K.P. Buteyko” after Buteyko’s death, when the inventors are listed as Ludmila and her son Andrey (see point 72)? This immediately suggests that the patent was not filed in order to use and protect the method described but for entirely different purposes.

When we read the description of the invention, we see that the method is based on the “MONITORING OF THE RATE OF CO2 INCREASE” in exhaled air and MAINTENANCE OF THE RATE of its increase. I don’t know about anyone else, but I don’t know a single practitioner who would practise such nonsense as MONITORING AND MAINTAINING THE RATE OF CO2 INCREASE!!! From this it immediately follows that it would be IMPOSSIBLE TO PRESENT A COURT WITH EVIDENCE OF THE USE of this patent by normal practitioners.

And there’s more! Look at point 56 of the patent! The book “The Buteyko Method… Moscow, Patriot 1990” [4] is indicated as a similar invention. This means that any practitioner can state that he is using methods from that book, and not the patent. The practitioner doesn’t need to present any proof that what he says is true – a reference to the book is already present in the patent presented to the court. In other words, the claimants need to present the court with ACTUAL evidence that you are using the infamous patent instead of the book. If you use other publications describing the methods that you use, you will need to show these publications to the court.

It is completely obvious that the circumstances described above will prove the impossibility of prosecution on the grounds of the patent. There is no dought that the case will be stopped dead during the preliminary examination of the claim. The patent owners are probably aware of this as I have not heard of a single prosecution using this patent.

Let’s now turn to trademarks.

I have heard of prosecutions using trademark no. 297512 (Appendix 2with a priority date of 2004.05.04 which contains the protected textual element “BUTEYKO” [in Latin script]. The same symbol but using Cyrillic text in Russian was filed as No. 103540 (Appendix 3with a priority date of 1991.10.24. These trademarks contain a lot of indications of heinous violations of trademark legislation. The most significant of these is the inclusion of words from the title of the class of services among protected elements of trademarks, as if these trademarks had been registered in order to individualise these services (see below). In other words, the trademarks themselves are constructed in such a way as to mislead consumers about the service provider. It would be difficult to use these violations as a defence in a court of law. They could only be used in attempts to have trademarks cancelled or to oppose their registration in other countries.

I would again recall that the LEGAL purpose of trademarks (in our case) is to IDENTIFY SERVICES. Obviously, no-one intended to call a service the “Society Buteyko Ltd”. It is impossible to imagine someone saying “Come and see us. We will PERFORM a Society on you” or “We charge such-and-such for a Society” and so on.

As with the patent, no-one intended to use these trademarks for their proper purpose!

It follows that it is easy to protect yourself from harassment in this instance as well, if you carefully study the trademarks and take precautionary measures.

To begin with, attention should be paid to point 526 “Unprotected elements”. It is clear from this point that the “intimidators” have tried to usurp the right to the surname Buteyko (Ludmila Novozhilova had the same aim in mind when she took advantage of the lack of Ukrainian legal restrictions to change her surname to Buteyko in around 1999). However, the trademark only restricts use of certain words in the name of services indicated in point 511. It is therefore sufficient for a practitioner to write “the VLDB Method of the inventor K.P. Buteyko” instead of “the Buteyko Method” to escape the trademarks as he is using the word “Buteyko” as the name of the inventor of a method (i.e. a person) and not of a service.

We also need to take a close look at point 511 “ICGS classes and list of goods and services”. In other words, this point indicates the area in which the trademark is valid. As is clearly stated, the trademark is only valid in the areas of classes 44 or 42 – medical aid or medical services, i.e. treatment of patients! (I don’t know if the numbers of classes of goods and services are the same in other countries.) It follows that if a practitioner always writes “training in the method” rather than “treatment by the method” then he can distance himself still further from the areas to which these trademarks apply.

Priority rights are another obstacle to trademark infringement claims. If a practitioner has registered a company to provide services with a name that uses the word “BUTEYKO” (in either Cyrillic or Latin script) before the priority date of this and, correspondingly, any other trademark, he has the right to use this word regardless of the rights of the trademark owner. In other words, the company name and the trademark have equal legal force under international law (see the Paris Convention for the Protection of Industrial Property, signed by numerous countries). I would also recommend studying Article 10-bis of this convention as it deals with many aspects of this problem and could be actively used as part of a defence in court.

Moreover, internet domain names have the same legal force as trademarks in many countries. This means that a practitioner or company for which he works that has registered an internet domain name before 2004.05.25 that uses the word “buteyko” will be sufficiently protected from trademark No. 297512 for the Latin script.

Many practitioners and organisations could defend themselves using the article of the law on the “exhaustion of rights” of trademark owners. In other words, if a document exists where the trademark owner has previously allowed you to use this symbol, or a protected element from this symbol, he cannot then accuse you of infringing his rights to the same trademark.

Etc., etc.

Conclusion 

In conclusion I suggest that we all remember a very important rule regarding workings of the human consciousness. In same situations, a moral person always makes fewer mistakes than an immoral one, all things being equal. I hope that this will give honest and thoughtful practitioners confidence in their ability to stand up to dishonest threats and intimidation.

References

1. Ture Wallén. Ryska Hälso revolutionen. Stockholm. 1983-1984. 83 pages. 
2. Бутейко К.П. Инструкция по применению способа волевой ликвидации глубокого дыхания (ВЛГД). Для самолечения врачей. Препринт. – Новосибирск, 1984 г. [K. P. Buteyko Instructions for the Application of the Voluntary Breath Normalization (VBN) Method. For the self-treatment of physicians: Preprint. – Novosibirsk, 1984.] [http://www.buteyko.ru/izdan/Buteyko_26_Instruction.pdf]
3. Бутейко К.П. Инструкция по применению способа волевой ликвидации глубокого дыхания (ВЛГД). Для методистов ВЛГД, прошедших специализацию под руководством автора. Препринт. – Новосибирск, 1988 г. [K. P. Buteyko Instructions for the Application of the Voluntary Breath Normalization (VBN) Method. For Buteyko practitioners trained by the author: Preprint. – Novosibirsk, 1988.] [http://www.buteyko.ru/izdan/Buteyko_63_Instruction.pdf]
4. Метод Бутейко: Опыт внедрения в медицинскую практику. Сборник/ Сост. К.П. Бутейко, А.Е. Хорощо. – Москва.- Патриот, 1990. -224 с. [Buteyko Method: Experience of introduction into medical practice. Collected papers. Compiled by K.P. Buteyko and A.E. Khoroshcho – Moscow, 1990. -224 p.] [http://www.buteyko.ru/izdan/metod_buteyko.zip]
5. Бутейко В.К., Бутейко М.М. Теория Бутейко о роли дыхания в здоровье человека : научное введение в метод Бутейко для специалистов / В.К. Бутейко, М.М. Бутейко. – Воронеж : ООО “Общество Бутейко”, 2005. – 100 с., илл. – Рус. / Англ. [V.K. Buteyko, M.M. Buteyko Buteyko’s theory of the key role of breathing in human health: scientific introduction to the Buteyko therapy for experts. Voronezh: Buteyko Co Ltd, 2005. 100p. – Rus. / Eng.] [http://www.buteyko.ru/izdan/Buteyko%20theory%20rus-eng.pdf]
Vladimir K. Buteyko



Appendix 1

No. 245171

The invention relates to the field of medicine and is designed to treat hypocarbia by decreasing pulmonary ventilation to a tolerable extent at a state of rest and during physical exertion while the CO2 content of expired air is monitored.

A method for treating haemohypocarbia in bronchial asthma is known from prior art, published as certificate of authorship No. 1067640, IPC (International Patent Classification) 7 A61 M 16/001

, which is characterised by decreasing lung ventilation to an extent that can be tolerated by the patient, monitoring the carbon dioxide concentration in exhaled air and maintaining its increase rate at not more than 3-7 mmHg per day until a level of 45-55 mmHg is reached. In spite of the advantages of this method, it is effective only in mild forms of bronchial asthma. The method described in certificate of authorship No. 1067640 can be regarded as a prototype of this invention. This invention aims to resolve the technical question of increasing the effectiveness of hypocarbia therapy by eradicating CO2 deficiency as a whole. 

This problem is solved by a method of treating hypocarbia diseases that consists of decreasing pulmonary ventilation to an extent that can be tolerated by the patient, monitoring the rate of carbon dioxide (CO2) increase in exhaled air and maintaining this rate. The decrease of pulmonary ventilation to an extent that can be tolerated by the patient is carried out at rest and during physical exertion. The rate of CO2 increase in exhaled air is maintained at not more than 2 mmHg per day at rest, and 11 mmHg during physical exertion, up to the level of 32.1 mmHg to eradicate acute symptoms, and up to 55 mmHg to obtain long-term clinical remission.

The invention is illustrated by clinical case histories. The CO2 content of exhaled air was measured by widely-known methods: the Capnograph, a widely-known standard apparatus, and a tested method to measure CO2 based on the method described in certificate of authorship No. 1593527. 

CLINICAL EXAMPLES 

Case history 1 
Treatment of Alveolar Hypocarbia 

P., 6 years old. Diagnosis: severe atopic bronchial asthma. Type II respiratory failure. Chronic vasomotor rhinitis. Polyvalent allergy. 
Complaints on admission: constant dyspnea, 6-7 asthma attacks, mainly during slight physical exertion and at night; constant cough with tenacious sputum, sometimes up to vomiting; laboured nasal breathing; general weakness; troubled sleep; irritability; tearfulness; itchy skin; constipation. 

Examination on admission: moderately severe condition. Practically no nasal breathing, rales audible at a distance, severe expiratory dyspnea. Pallid skin. Auscultation identified: diffuse high and low-pitched dry rales and medium moist rales over the entire area of both lungs. Vesiculotympanitic resonance. Respiratory rate=30 per min. Heart: sounds muffled, heart rate=118 per min, regular rhythm, blood pressure=100/60 mmHg. Geographic tongue, abdominal wall tenderness on palpation in the epigastric area and in the right hypochondrium. Control pause=3 sec, pCO2 =22.4 mmHg. 
P. mastered the method instantly. In 10-15 minutes his asthma symptoms resolved: nasal breathing improved, cough and dyspnea decreased, and heart rate reduced to 100 beats per minute. From the point of view of auscultation, the number of high-pitched dry rales was reduced, RR=20 per minute. On the sixth day of treatment the CP increased to 9-10 seconds, and the level of pCO2 went from 27.3 up to 31.8 mmHg. Asthma attacks had completely stopped and there was no need for drug therapy. The boy was considerably more active, and his physical stamina had improved. 
On the 14th day the CP increased to 20 seconds and pCO2 to 35.6 mmHg, accompanied by a further decrease in dyspnea, normalisation of sleep patterns, improved appetite, and reduced weakness and sweating. 
Clinical manifestations of allergy disappeared, including reaction to smells, when the CP reached 30-40 seconds. On examination, the patient’s condition was satisfactory. The skin and visible mucosa were clear and of normal colour. Breathing in lungs was vesicular, with harsh breath sounds in the lower parts. RR=14 per minute. Heart: clear sounds, heart rate: 80 per min, BP=90/60 mmHg. The tongue was moist with no abnormalities. The abdomen was soft and pain-free.
During the follow-up period after 6 months there were no acute attacks of bronchial asthma or allergic reactions, and stable remission was achieved. 

Indicators                                 CP = 3 sec         CP = 40 sec 
Vital capacity (litres)                  0.3                         1.5
pCO 2 mmHg                             27.3                         35.6
Clinical blood analysis: 
leucocytes                                9.2 × 10/1                 7.2 × 10/1 
eosinophiles                             23                         3
banded neutrophils                     1                         5
segmented neutrophils             40                         54
lymphocytes                             31                         37
monocytes                                 5                         1
erythrocyte sedimentation rate 9 mm/h                 9 mm/h 


A chest X-ray when the CP was 40 seconds (one month after the beginning of treatment) showed that the lower parts of lung fields were more transparent, and the lung bases were firmer. There were no infiltrative and focal changes. The heart showed no peculiarities. 
Case history 2 


Treatment of Alveolar Haemohypocarbia 
N., 8 years old. Diagnosis: mild mixed bronchial asthma. Type 1 respiratory failure. Adenoidectomy in 2002. Chronic year-round vasomotor rhinitis, presenting with an acute flare. Atopic dermatitis. Chronic gastritis, in remission. 
Complaints on admission: absence of nasal breathing, mucus secretion from nose, cough with mucoid sputum worse at night. 
Clinical examination on admission: Satisfactory condition. Skin clear, cheeks dry. No nasal breathing. Facial puffiness, conjunctival hyperemia. Harsh sounds in lungs, small number of diffuse high-pitched dry rales over the entire area of both lungs. RR=18 per minute. Heart: clear sounds, heart rate: 100 per minute, regular rhythm, BP=100/60 mmHg. Abdomen was soft and pain-free. Maximum pause=12 sec, pCO2 =29 mmHg. 
From the first days of exercise, nasal breathing was restored against a background of a reduction in depth of breathing during physical activity. 
After seven days there was free nasal breathing, with no nasal secretions. Hacking and laboured nasal breathing at night continued. MP increased to 16 seconds, pCO2 to 300 mmHg. 
After 14 days: no complaints. 
Examination: Satisfactory condition. Skin was clear. Free nasal breathing. Vesicular breathing in lungs, no rales. RR=18 per minute. Heart: clear sounds, heart rate: 90 per minute regular rhythm, ABP: 90/60 mmHg. Abdomen was soft and pain-free. MP=20 sec, pCO 2 =32.1 mmHg. 


Indicators                         MP = 12 sec          MP = 20 sec 
Clinical blood analysis: 
leucocytes                         8.9 × 10/1             4.5 × 10/1 
eosinophiles                       7                            4
banded neutrophils             6                            1
segmented neutrophils       54                           63
lymphocytes                     30                           27
monocytes                        3                            5
ESR                                 26                         13
pCO 2 mmHg                    29                         32.1
Case history 3 
Treatment of Alveolar Hypocarbia 
K., 9 years. Diagnosis: moderate mixed bronchial asthma, presenting with an acute flare. Polyvalent allergy to food and household allergens. Chronic gastritis. 
Complaints on admission: dry attack-like cough, worse at night, dyspnea during physical activity, asthma attacks at night and up to 2-3 times in the daytime. 
Examination on admission: moderately severe condition. Pale and clear skin. Marked cyanosis of nasolabial triangle. Harsh sounds in lungs, diffuse multiple high-pitched dry rales over the entire area of both lungs. RR=24 per minute. Heart: sounds were muffled, heart rate=120 per minute. MP=3 sec., pCO 2 =22.4 mmHg. 
During the first hour of exercises the control pause increased to nine seconds and pCO2 to 28 mmHg. The attack was stopped. 
After six months: K. felt well, but hacking remained as a result of poor diet. MP=70 sec., pCO 2 =47 mmHg. K. had not taken drugs for the previous four months.

Indicators                         MP = 3 sec     MP = 70 sec 
Clinical blood analysis: 
leucocytes                         5.2                     7.06
banded neutrophils
segmented neutrophils         42.0                    34.7
lymphocytes                       41.2                  49.6
monocytes                         8.4                     7.5
eosinophiles                       8.0                     5.1
basophiles                         0.4                     0.4
Immunoglobuline levels: 
IgG (ME/ml)                     102                     174
IgA (ME/ml)                     138                     160
IgM (ME/ml)                     95                     73
IgE (ME/ml)                     29                     29
IgD (ME/ml)                                          :  
Lymphocyte subsets of the immune system
T-lymphocytes                     60.0%             63.5%
T-helpers                             35.3%             46.4%
T-supressors                         29.2%             19.2%
Helper/suppressor cell ratio     1.2                     2.4
Natural killers                         9.9%                 14.2%
B-lymphocytes                                             4.6%
Activated lymphocytes 
expressing receptors                                     3.6%
Mononuclears                                             91.2%
HLA-DR+(monocytes, 
B-lymphocytes, 
activated 
T-lymphocytes)                                             6.2%
Phagocytic activity of 
neutrophils: 
spontaneous in
conventional units         0.16                     0.29
induced in
conventional units         0.26                     0.35
stimulation ratio             1.6                     1.4
neutrophil adhesion     57.1%                     58.7%
Antioxidant status: 
Malonic aldehyde
concentration             3.2 mcmol/ml     4.5 mcmol/ml 
Lactoferrin
concentration             1.0 mg/ml             1.0 mg/ml 
Catalase activity
in conventional units     982.0                     1074
Ceruloplasmin activity
in conventional units     0.54                     0.56
Oxidant-antioxidant
ratio                             1.7                     1.6
Interferon status: 
spontaneous interferon    <2                     <2 
alfa – interferon             320                     320
gamma – interferon         32                      32
serum interferon             <2                     2
pCO2 mmHg                 22.4                     47
Case history 4 
Treatment of Haemohypocarbia 
Ch., 67 years old. Diagnosis: coronary heart disease, exertional and rest angina NYHA class III, postinfarction cardiosclerosis (large-focal myocardial infarction). Third stage hypertension. Class IIa cardiac insufficiency2. Second stage hypoxic encephalopathy of complex origin (hypertension and cerebral atherosclerosis). Effects of an acute stroke in the right hemisphere. 

Complaints on admission: angina attacks during insignificant physical exertion and at rest, dizziness, frequent disorientation. Ch. took up to 15 tablets of Nitroglycerin, Sustac-forte four times daily, and Cordarone 0.2 three times daily3.
 
CP=3 sec, pCO2 =22.4 mmHg. 
After 21 days: CP=15 sec, pCO2 = 29 mmHg. Patient felt well with angina attacks occurring only during excessive exercise. Blood pressure was normalised and the patient only took nitro medicines when experiencing heart pains.
After 3 months: The patient stopped taking medicines. Heart pains occurred no more than 1-3 times monthly and were stopped by the method. He walked 10-15 km at a brisk pace daily and could run 100-200 metres. 
After 1 year: CP=35 sec, pCO2 =39 mmHg. 
An ECG showed a positive change: a negative T wave in leads V2-V4 changed to a positive T wave.
The haemohypocarbia therapy described in the certificate of authorship filed by K.P. Buteyko No. 1067640 was previously used to treat the diseases described above. The essence of this therapy is to normalise the CO2 content of blood in order to treat bronchial asthma. However, in moderate and severe bronchial asthma, blood CO2 content is already above normal. The “old” method can therefore only be used in milder forms of bronchial asthma where there is a deficiency of CO2 in the alveoli and the blood. 
Both methods can hence be used to treat mild bronchial asthma and all the other diseases described above, and the “new” method (hypocarbia therapy) can be used to treat mild, moderate and severe forms of bronchial asthma and all the other diseases (i.e. diseases caused by a deficiency of CO2 , in this case in alveolar air: alveolar hypocarbia). This invention is the Buteyko Method – a method for treating hypocarbia that leads to long-term remission of the diseases described above.
The eradication of hypocarbia results in recovery from the following diseases: 
Acute diseases (pneumonia, bronchitis, etc) and chronic diseases of the respiratory system, such  as chronic obstructive bronchitis, bronchial asthma (at any stage and in any form), pulmonary emphysema, diffuse or focal pneumosclerosis, bronchiectasis; 

Cardiovascular diseases: hypertension, ischaemic disease (at any stage and in any form); Allergic diseases: chronic vasomotor rhinitis, hay fever, urticaria, atopic dermatitis, etc.; Secondary immunodeficiency;

Gastrointestinal diseases: chronic gastroduodenitis, stomach and duodenal ulcers, chronic cholecystitis, chronic pancreatitis, etc. 

Description of the invention

A method for treating hypocarbia diseases and conditions, characterised by reducing pulmonary ventilation to an extent that can be tolerated by the patient, monitoring the rate of carbon dioxide (СО2) increase in expired air and maintaining this rate of increase. This method is distinguished by the fact that the reduction in pulmonary ventilation is performed at rest and during physical exertion and that the rate of СО2 increase in expired air is maintained. This rate does not exceed 2 mmHg in 24 hours while the patient is resting and 11 mmHg during physical exertion, until a level of 32.1 mmHg is reached allowing symptoms to be eradicated and 55 mmHg allowing long-term clinical remission.

Translator’s notes

1. The ‘certificate of authorship’ (also sometimes translated as ‘author’s certificate’, ‘certificate of invention’ or ‘inventor’s certificate’) was a type of patent issued in the USSR entitling the inventors to compensation, with the government holding invention rights.

2. This appears to be a reference to the Vasilenko-Strazhesko classification of heart failure.

3. This sentence is unclear in the original, perhaps due to a typing mistake.


Appendix 2

No. 297512



Appendix 3

No. 103540

Russian Federal Service for Intellectual Property, Patents and Trademarks

(ROSPATENT)

(190) RU (111) 103540

Trade and service marks 
Status: according to information at 19.02.2007 – valid

(220)
Date of filing: 1991.10.24 

(151)

Date of registration: 1992.03.16 

(210)
Application number: 143051 

(181)

Registration expiry date: 2001.10.24 

(450)
Date of publication: 1994.03.25

(731)
Owner: Limited Liability Company “Obshchestvo Buteyko Ltd” Moscow (RU) 

(526)

Unprotected elements: The word “obshchestvo” [society, company] and the letters “Ltd” are not subject to separate legal protection

(540) 



(511)
ICGS (International Classification of Goods and Services) classes and list of goods and services:

42 – medical services (treatment of patients based on the VEDB method of K.P. Buteyko) 


NOTIFICATION OF CHANGES RELATING TO TRADEMARK REGISTRATION


Bulletin publication date

2002.06.25
Change code
Change in the company name, surname, given name or patronymic of the owner
(732) Name and address of owner
LLC “Buteyko i K”, Building 2, 3 3rd Vladimirskaya Street, 111123 Moscow
(771) Former name and address of applicant or owner

LLC “Obschestvo Buteyko, Ltd”, Building 2, 3 3rd Vladimirskaya Street, 111123 Moscow


Bulletin publication date

2002.06.25
Change code
Extension of trademark validity
(732) Name and address of owner
LLC “Buteyko i K”, Building 2, 3 3rd Vladimirskaya Street, 111123 Moscow
(186) Extension expiry date
2011.10.24

Bulletin publication date

2002.06.25
Change code
Issue of a copy of the trademark certificate
(732) Name and address of owner
LLC “Buteyko i K”, Building 2, 3 3rd Vladimirskaya Street, 111123 Moscow
Operation registration date
2001.11.21

Document
In PDF format
Bulletin publication date
2006.05.12
Change code
Registration of a trademark assignment agreement in respect of all goods and/or services
(732) Name and address of owner
Ludmila Dmitrievna Buteyko, Flat 21, 51 Perovskaya Street 111141 Moscow
(770) Name and address of owner
Limited Liability Company “Buteyko i K”, Building 2, 3 3rd Vladimirskaya Street, 111123 Moscow
Operation registration date
2006.03.21
Operation registration number
RD0007372



Interesting Buteyko Knols



%d bloggers like this: